Alivus Life Sciences Limited (NSE:ALIVUS)

Market Cap	127.64B
Revenue (ttm)	23.87B
Net Income (ttm)	4.86B
Shares Out	122.63M
EPS (ttm)	39.52
PE Ratio	26.34
Forward PE	23.44
Dividend	5.00 (0.48%)
Ex-Dividend Date	n/a

Volume	108,842
Average Volume	89,654
Open	1,063.10
Previous Close	1,061.60
Day's Range	1,031.90 - 1,080.90
52-Week Range	850.00 - 1,251.00
Beta	0.19
RSI	40.49
Earnings Date	Jul 23, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 2,014
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALIVUS

Financial Performance

In 2024, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.